Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toca 511 and Toca FC with Standard of Care in Newly Diagnosed Glioblastoma
NCT04105374Phase 3Withdrawn
- Sponsor
- NRG Oncology
- Start
- Jan 2020
- Primary completion
- Nov 2025
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
01
Overview
A Phase 3 trial of vocimagene amiretrorepvec, flucytosine in glioblastoma (GBM), sponsored by NRG Oncology. Planned start Jan 2020; status: withdrawn.
02
Drugs
vocimagene amiretrorepvecflucytosine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04105374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04105374.